Scopus
🔓 Açık Erişim YÖKSİS Eşleşti
Assessment of serum vascular endothelial growth factor, nitric oxide and asymmetric dimethyl arginine levels in non-small cell lung cancer
Northern Clinics of Istanbul · Ocak 2025
YÖKSİS Kayıtları
Assessment of serum vascular endothelial growth factor, nitric oxide and asymmetric dimethyl arginine levels in non-small cell lung cancer
Northern Clinics of İstanbul · 2024 TR DİZİN
PROFESÖR HÜSAMETTİN VATANSEV →
Assessment of serum vascular endothelial growth factor, nitric oxide and asymmetric dimethyl arginine levels in non-small cell lung cancer
Northern Clinics of İstanbul · 2024 TR DİZİN
DOÇENT FARİSE YILMAZ →
Assessment of serum vascular endothelial growth factor, nitric oxide and asymmetric dimethyl arginine levels in non-small cell lung cancer
Northern Clinics of Istanbul · 2025 SCI-Expanded
PROFESÖR ALİ ÜNLÜ →
Makale Bilgileri
DergiNorthern Clinics of Istanbul
Yayın TarihiOcak 2025
Cilt / Sayfa12 · 45-54
Scopus ID2-s2.0-85218784031
Erişim🔓 Açık Erişim
Özet
OBJECTIVE: Lung cancer is one of the most prevalent malignancies worldwide, with 80–85% of cases diagnosed as non-small cell lung cancer (NSCLC). The majority of NSCLC patients present with advanced disease, contributing to high mortality and limited treatment options. Angiogenesis, a crucial process in cancer progression, is largely regulated by growth factors and cy-tokines. Vascular Endothelial Growth Factor (VEGF) is a key regulator of angiogenesis. Asymmetric Dimethyl Arginine (ADMA) inhibits endothelial nitric oxide synthase (eNOS), leading to reduced nitric oxide (NO) release and subsequent endothelial dysfunction. The aim of this study is to investigate the serum levels of ADMA, NO, VEGF and several tumor markers including Carcinoembryonic Antigen (CEA), Cancer Antigen 125 (CA 125), Neuron Specific Enolase (NSE), Lactate dehydrogenase (LDH) and Cyfra 21-1 in NSCLC patients to assess their potential role in early diagnosis, tumor invasion, and staging of the disease. METHODS: Our study consisted of 56 newly diagnosed NSCLC patients and 32 controls with similar demographic charac-teristics. Patients with chronic diseases and inflammatory disorders were excluded. Statistical analysis was conducted using R Statistical Software. RESULTS: In our study, compared to the control group, the serum VEGF, NO, ADMA, CA 125, CEA, Cyfra 21-1 and NSE levels were significantly higher in NSCLC group (p=0.001, p=0.013, p=0.041, p<0.001, p<0.001, p<0.001 and p=0.001, respectively). In the diagnosis of NSCLC, Cyfra 21-1 exhibited the highest diagnostic efficacy with a 71% sensitivity and 94% specificity. The combination of VEGF, CA125, and Cyfra 21-1 showed a 73% sensitivity and 100% specificity, while the combination of CA125, CEA, and Cyfra 21-1 achieved an 85% sensitivity and 91% specificity. CONCLUSION: Our study revealed that the serum concentrations of VEGF, NO, ADMA, CA125, Cyfra 21-1, CEA, and NSE were significantly elevated in patients with NSCLC compared to the control group, and that levels of Cyfra 21-1, LDH, and NSE increased with advancing TNM stage. The combination of markers distinguished NSCLC with high sensitivity and specificity. Further studies involving larger populations, including those with benign lung diseases, are needed to validate and expand upon our findings.
Yazarlar (6)
1
Esra Paydas Hataysal
ORCID: 0000-0002-3538-8135
2
F. Kanat
3
M. K. Korez
ORCID: 0000-0001-9524-6115
4
F. Yilmaz
5
Ali Ünlü
ORCID: 0000-0002-9991-3939
6
Hüsamettin Vatansev
Anahtar Kelimeler
ADMA
CA125
Cyfra 21-1
lung cancer
NO
VEGF
Kurumlar
Goztepe Prof. Dr. Suleyman Yalcin City Hospital
Istanbul Turkey
Selçuk Tip Fakültesi
Konya Turkey